European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...

GlaxoSmithKline LLC (GSK) plans to lay off 150 Cambridge workers. The layoffs come months after GSK said it had planned to ...

The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's ...

GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...

Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab mafodotin) ...

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s ...

GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

Oncologic Drugs Advisory Committee has voted against two proposed combination regimens containing GSK’s Blenrep (belantamab ...